Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.
Following recent reports suggesting that the addition of cimetidine to interferon may enhance response rates in patients with metastatic malignant melanoma, we have completed a Phase II study of the use of recombinant alpha 2 interferon and cimetidine in patients with advanced malignant melanoma and who had progressive disease following interferon therapy alone. We observed two partial responses, no complete responses, and two patients had stable disease. Toxicity encountered was analogous to that of interferon alone. We conclude that the additional of cimetidine to alpha interferon is not beneficial in the treatment of advanced metastatic malignant melanoma.
Mughal
T I
TI
Melanoma Clinic Research Center, University of Colorado Health Sciences Center Denver 80262.
Robinson
W A
WA
Thomas
M R
MR
Spiegel
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002927:Cimetidine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D007370:Interferon Type I / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D007370:Interferon Type I; D011994:Recombinant Proteins; D002927:Cimetidine